Multiple Myeloma Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Leukemia. 2014 Jul;28(7):1423-6. doi: 10.1038/leu.2014.22. Epub 2014 Jan 14.
The last decade has seen significant advances in the management of patients with multiple myeloma (MM). With increasingly effective therapies, MM patients are living longer. With improvements in survival, long-term complications including second primary malignancies are becoming new challenges in providing optimal care for MM patients. Three randomized studies have demonstrated possible clinical benefit with maintenance lenalidomide for patients with MM. These same studies have also demonstrated an increased risk of second primary malignancies. In this review, we will update on the current information regarding mechanisms and risk of developing second primary malignancies with a particular focus on disease- and treatment-related factors.
过去十年中，多发性骨髓瘤（MM）患者的治疗取得了重大进展。随着治疗方法的日益有效，MM 患者的寿命越来越长。随着生存的改善，长期并发症，包括第二原发恶性肿瘤，成为为 MM 患者提供最佳护理的新挑战。三项随机研究表明，维持来那度胺治疗 MM 患者可能具有临床获益。这些相同的研究也表明第二原发恶性肿瘤的风险增加。在这篇综述中，我们将更新目前关于第二原发恶性肿瘤的发病机制和风险的信息，特别关注与疾病和治疗相关的因素。
